Story
Moderna Stock Rises on Barclays Price Target Hike, Broader Market Strength

Moderna (MRNA) shares rose 2.9% in pre-open trading, rebounding from a multi-session pullback with support from a key analyst price target revision and a broader market rally.
Analyst Boosts Outlook
A primary catalyst for the move was a note from Barclays published late Monday. Analyst Eliana Merle raised the firm's price target on Moderna to $125 from a previous $48, while maintaining an Equal Weight rating on the shares.
This follows an earlier upgrade from Wolfe Research, which moved its rating to Peerperform from Underperform after the company's recent clinical trial success. Wolfe analysts estimated unadjusted peak sales for the therapy could reach $9.2 billion across four potential cancer indications, before accounting for its profit-sharing agreement with partner Merck.
Market Context and Rebound
Tuesday's rally is also supported by a constructive market environment. A risk-on tone across U.S. equities, with the Nasdaq Composite up 1.0% and the S&P 500 up 0.5% in pre-market, is providing a tailwind for high-growth, high-beta stocks like Moderna.
AdThe stock's move comes after a period of profit-taking. Shares have been highly volatile following a year-to-date surge of 392%, driven by breakthrough clinical data. The recent decline was attributed to investor consolidation and broader sector pullbacks.
Background: Cancer Vaccine Breakthrough
The stock's significant recent performance is tied to the landmark Phase 3 trial success of its personalized mRNA cancer vaccine, intismeran autogene, co-developed with Merck. The trial met its primary goal, demonstrating a meaningful reduction in the recurrence of melanoma in patients after surgical tumor removal.
This result marked the first positive late-stage trial for an mRNA-based cancer vaccine, a major milestone for the technology. While the stock remains well below its 52-week high of $176.66, analysts see a potential commercial launch for the vaccine in 2027 if interim data remains positive, underpinning long-term investor interest.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.